Rituximab, a B cell–depleting anti-CD20 chimeric monoclonal antibody, is Food and Drug Administration approved in the United States for the treatment of certain lymphomas, rheumatoid arthritis, and granulomatous and microscopic polyangiitis. It has been used additionally in a wide variety of glomerular disorders including lupus nephritis, IgA nephropathy, minimal change disease and focal segmen...

Abstract Background and Aims Idiopathic membranous nephropathy (IMN) is an organ-specific autoimmune disease of the kidney glomerulus. Although substantial advances have been made in understanding molecular bases IMN last 10 years, there remain largely unanswered questions. Method To define transcriptomic landscape at single-cell resolution, we analyzed samples from 6 patients with idiopathic 2...